CAMKK2 and autosomal dominant polycystic kidney disease: STO-609, a cell-permeable and selective CaMKKβ inhibitor (Tokumitsu et al., 2002), decreased P-AMPK/AMPK in ADPKD cells (Figure 5A and B), as expected; however, the reduction in P-AMPK did not increase mTOR activity (Figure 5A and C).